Unilife to Supply Hikma with Prefilled Syringes for Generic Injectables - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Unilife to Supply Hikma with Prefilled Syringes for Generic Injectables
Unilife to begin commercial supply in 2014.


Unilife Corporation, a US-based developer and commercial supplier of injectable drug-delivery systems, has signed a 15-year agreement with Hikma Pharmaceuticals, in which Unilife will supply customized prefilled syringes to Hikma for a range of generic injectable drugs.

Hikma has selected an initial list of 20 generic injectable products to be formulated using Unilife’s proprietary platform (branded as Unifill) of prefilled syringes with automatic and fully integrated needle retraction.

Under the terms of the agreement, Hikma holds exclusive global rights to its generic products using Unilife’s Unifill platform. Additional injectable drugs may also be added to the exclusivity list subject to agreement by both parties.

In return, Unilife will receive $40 million in upfront and milestone payments. An initial upfront payment of $5 million will be paid to Unilife immediately, with an additional $15 million in payments expected during 2014. The final $20 million in milestone-based payments will be paid the following year.

Unilife will start supplying the products to Hikma in early 2014, with a minimum supply volume expected to exceed 175 million units per year.

Source: Unilife

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here